Delayed follow-up in patients with diabetic retinopathy in South India: Social factors and impact on disease progression

Natrajan Vengadesan, Meleha Ahmad, Manavi D Sindal, Sabyasachi Sengupta

Purpose: To identify social factors associated with delayed follow-up in South Indian patients with diabetic retinopathy (DR) and to study DR progression during the delayed follow-up period.

Materials and Methods: In this cross-sectional study, 500 consecutive patients with DR returning after greater than twice the advised follow-up period were identified from a tertiary referral center in South India. A previously validated 19-item questionnaire was administered to study patients to assess causes for the follow-up delay. Patient demographics, DR status, and treatment plan were recorded at the study visit and the visit immediately before the delay. The eye with the most severe disease was included in the analysis.

Results: Complete data were available for 491 (98.2%) patients. Among these, 248 (50.5%) cited “my eyes were okay at the time,” 201 (41.0%) cited “no attender to accompany me,” and 190 (38.6%) cited “financial cost” as causes of the follow-up delay. Those with vision-threatening DR (VTDR, n = 233) predominantly reported “financial cost” (47% vs. 32%, \(P = 0.001\)), whereas those with non-VTDR more frequently reported “my eyes were okay at the time” (58% vs. 42%, \(P = 0.001\)). Evidence of disease progression from non-VTDR to VTDR was seen in 67 (26%) patients. Almost 1/3 (29%) of patients who were previously advised regular examination required additional intervention. Conclusion: Many patient-level factors affect poor compliance with follow-up in DR, and these factors vary by disease severity. Targeting these barriers to care through patient education and clinic procedures may promote timely follow-up and better outcomes in these patients.

Key words: Compliance, delayed follow-up, diabetes, diabetic retinopathy, South India

Diabetic retinopathy (DR) is a chronic disorder of the microvasculature of the retina, affecting roughly 93 million patients worldwide. Although the sequelae of untreated DR can be debilitating, repeated studies have shown that timely treatment can significantly reduce visual loss in patients with DR. Despite this, patient compliance with timely follow-up remains a significant barrier to prevent severe vision loss in the diabetic population.

DR is expected to become an increasingly common cause for morbidity in the developing world over the coming decades. There has been a well-documented rise in the rates of diabetes in the developing world, with India’s prevalence expected to increase 3-fold by the year 2025. Population-based studies in South India have demonstrated rates of DR to be 12.2%–18.0% within the urban diabetic population, slightly lower than rates in the West but likely to be offset by the sharp rise in diabetes prevalence in India. The overall prevalence rates of DR in India have been seen to vary between 3.5% in urban populations and approximately 1.1% in rural populations.

A number of studies have investigated causes for lapses in follow-up in the medical and surgical settings, citing transportation and financial difficulties as common patient-level factors. In the ophthalmological setting, follow-up in glaucoma has been widely studied in both the developing and developed world. A study in South Indian glaucoma patients identified major barriers being the belief that there was no problem with one’s eyes and the lack of an escort, whereas a similar study in a Western population cited financial difficulties, doctor–patient miscommunication, and their condition being “not serious enough” to warrant follow-up. Interestingly, a study comparing ophthalmologic follow-up rates in patients with diabetes and glaucoma found lower compliance in diabetes compared with glaucoma, although the causes were not explored. Diabetes itself is a known risk factor for appointment noncompliance in the medical setting.

Early detection of DR and prevention of visual loss depend on patients reporting to clinic in a timely manner. Understanding the local factors that contribute to low compliance rates will allow the development of policies and interventions to increase visit compliance and promote timely intervention. We performed this study to understand the factors associated with delayed follow-up in a South Indian population and to assess the progression of disease that occurs during this delay.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

Cite this article as: Vengadesan N, Ahmad M, Sindal MD, Sengupta S. Delayed follow-up in patients with diabetic retinopathy in South India: Social factors and impact on disease progression. Indian J Ophthalmol 2017;65:376-84.
Materials and Methods

This study was conducted in the retina clinic of a tertiary eye care hospital in South India over a 6-month period (June to December 2014). The study protocol was approved by our Institutional Review Board and Ethics Committee and adhered to the tenets of the Declaration of Helsinki. Informed consent was obtained from all patients. Patients with diabetes with or without previously diagnosed DR returning for follow-up after a delay were deemed eligible for the study. A delay was defined as greater than twice that of the recommended follow-up period and was calculated as the time interval (in months) between the recommended follow-up date and the eventual date of presentation. Patients of any age, gender, stage of DR, and those advised to return for either routine follow-up, investigations (angiography, optical coherence tomography, etc.), or interventions (laser photocoagulation, intravitreal injection, or surgery) were included in the study. Patients with retinal pathology in addition to DR (coexistent retinal vein occlusion, macular degeneration, etc.) were excluded from the study.

After obtaining informed consent, a standardized questionnaire was administered to each study participant. The questionnaire used previously by our group to study compliance rates in glaucoma follow-up[17] was modified in-house for this study. In the initial phase of questionnaire modification, patients returning for follow-up after a delay were asked open-ended questions about the reasons for the delay. These responses, along with input from key members of the patient care team including physicians, nurses, counselors, and patient care coordinators, were compiled to create a modified questionnaire. This was administered to a pilot group of 21 patients returning after a delay in follow-up for questionnaire validation. Additional changes were made based on this pilot and were incorporated into the final questionnaire administered to the study participants.

The questionnaire consisted of three sections. Section A recorded baseline demographics such as age, gender, marital status, residence (urban vs. rural), education, family structure (nuclear vs. joint family), occupation, income, and insurance status. Section B included clinical findings from the patients’ previous and current visit. All patients were examined by one of four fellowship-trained retina specialists. The details of the previous visit were recorded from available medical records, including previous intervention in the form of laser (panretinal photocoagulation or macular), intravitreal injection (anti-vascular endothelial growth factor [VEGF] or steroids), or vitreoretinal surgery for DR. Ophthalmic status was noted at the time of patient recruitment, including best-corrected visual acuity (BCVA), coexisting ocular conditions such as cataract, comprehensive slit lamp, and dilated fundus examination for staging of DR severity based on the Early Treatment Diabetic Retinopathy Study (ETDRS) criteria. Vision-threatening DR (VTDR) was defined as the presence of severe nonproliferative DR (NPDR), early/high-risk/treated but unstable proliferative DR (PDR), or the presence of diabetic macular edema (DME) irrespective of stage of background DR. PDR was described as “stable” if no active neovascularization or fresh vitreous hemorrhage was noted clinically in a previously treated eye, and eyes with stable PDR were classified as non-VTDR for this study.

The examining physician had advised the initial follow-up based on standard ETDRS guidelines. In cases where investigation or intervention had been advised, standard protocol-based institutional guidelines were followed (usually within 5–15 days, depending on disease severity). The initial date for follow-up was noted from the counselor’s notes in the patient’s records, and the duration of delay (in months) was calculated as per the definition mentioned above. Reasons for the current visit (such as vision loss, routine checkup, investigation, and intervention) and details of recommended treatment and follow-up instructions at the current visit were also recorded.

Section C consisted of questions pertaining to the reason for delay. A 19-point questionnaire with yes/no response options for each item was administered by trained paramedical staff, and participants were permitted to answer yes to all questions that applied. A comments section for reasons not included in the questionnaire was available. The questionnaire was prepared in English but administered to the patients in their vernacular language (Tamil). Sections A and C were completed with help of paramedical staff while section B was completed by any one of four fellowship-trained retinal specialists.

Statistical analysis

The worse eye from each patient was chosen for statistical analysis. In cases of asymmetric eye disease, the eye with the more advanced DR during the previous visit or greater worsening of DR severity between the previous and current visit was chosen. When both eyes had the same disease severity, the right eye was chosen for analysis. The overall prevalence of answering “yes” to each item in the questionnaire was calculated, and differences in responses between patients with VTDR and non-VTDR (based on the previous visit) were analyzed using Chi-square or Fisher’s exact test. In addition, patients who had shown a significant disease progression, defined as either severe NPDR to PDR or non-VTDR to VTDR in at least one eye were identified, and the prevalence of various social factors in patients with and without disease progression was compared using Chi-square test. Average vision for the group was compared before and after follow-up delay using a paired t-test. Differences in treatment plan between the current and previous visit were also compared to better understand disease progression during the delayed follow-up period. Continuous variables were presented as mean ± standard deviation or median with interquartile range (IQR), and group differences were analyzed using Student’s t-test or Wilcoxon rank-sum test. All data were entered in Microsoft Excel sheets and analyzed using STATA 12 I/c (STATA Corp., Texas, USA).

Results

Five hundred consecutive patients with DR satisfying the inclusion criteria were interviewed. Complete data were available for 491 (98.2%) of 500 patients. At baseline, 233 patients (47.5%) had VTDR. Overall, the mean duration of delay in follow-up was 13 months ± 12.7 months (Median = 9, IQR = 5–16 months). The baseline sociodemographic characteristics of the study population are outlined in Table 1. The average age was 60 years, 90% had at least some education, most had traveled long distances (>75 km), and almost 80% did not have health insurance coverage. Compared to patients with non-VTDR, those with VTDR were more likely to be younger,
male, and to have traveled long distances for care [Table 1]. Those with non-VTDR had a greater delay in follow-up compared to those with VTDR (median = 10.5 months, IQR = 6–17 months vs. median = 8 months, IQR = 4–16 months, \( P = 0.006 \)).

The prevalence of various factors that contributed to a delay in follow-up is summarized in Table 2. Nearly 2/3rd of those with non-VTDR at baseline quoted “my eyes were okay the time” as the cause for their delay in follow-up compared to <1/2 of those with VTDR at baseline. In contrast, there were significantly more VTDR patients who quoted “financial cost” as their primary cause for the delay. In both groups, more than 20% of patients reported “checkup with other ophthalmologist” as a reason for the delay in follow-up.

Progression of DR status during the delayed follow-up period is summarized in Table 3. Of the 219 patients with non-VTDR, 42 (19%) progressed to VTDR. In addition, 24 out of 76 with severe NPDR progressed to PDR (32%). Overall, 67 patients (23%) showed progression of DR/DME as per our predefined criteria. Among patients with DR progression, “my eyes were okay at the time” was again the most common (55%) reason quoted. A significantly greater proportion of those who showed DR progression reported a delay because of “no attender to accompany me” (49% vs. 34%, \( P = 0.03 \)), but there were no other differences in reasons for delayed follow-up between these two groups. In addition, those who showed disease progression had a lengthier delay in follow-up compared to those who did not (median = 14 months, IQR = 7–22.5 months, vs. median = 9 months, IQR = 5–16 months, \( P = 0.004 \)).

In eyes with preexisting PDR or high-risk PDR (\( n = 196 \)), 32 (16%) were treatment naive, 75 (38%) had been advised additional intervention for unstable PDR with ongoing neovascular processes, and the remaining (45%) had stable lasered PDR that required only periodic follow-up. Mean vision worsened by approximately three logMAR lines (from \( 0.36 \pm 0.5 \) logMAR to \( 0.64 \pm 0.55 \) logMAR, \( P < 0.001 \)). At least one line drop in BCVA was seen in 230 (47%) eyes. There were no differences in reasons for delayed follow-up between those with vision loss and those without.

Nearly 1/3rd of previously untreated patients were advised to undergo more aggressive treatment for DR at the time of his or her delayed follow-up visit [Table 4]. This included patients who had been previously advised regular follow-up examination but were now advised to undergo additional

---

### Table 1: Baseline sociodemographics of the study population

|                            | Overall (\( n=491 \)) | Non-VTDR (\( n=258 \)) | VTDR (\( n=233 \))^* | \( P \)  |
|---------------------------|------------------------|-------------------------|----------------------|------|
| Age (years)               | 59±9.1                 | 61±9.2                  | 57.1±8.6             | <0.001** |
| Gender (%)                |                        |                         |                      |      |
| Men                       | 336 (68)               | 163 (63)                | 173 (74)             | 0.008* |
| Marital status (%)        |                        |                         |                      |      |
| Married                   | 89                     | 86                      | 93                   | 0.16* |
| Unmarried                 | 1                      | 1                       | 1                    |      |
| Other (widowed/divorced)  | 10                     | 13                      | 7                    |      |
| Residence (%)             |                        |                         |                      |      |
| Rural                     | 168 (36)               | 76 (30)                 | 92 (41)              | 0.02* |
| Travel distance to hospital (km) | 75.2±87.7             | 67.4±63                 | 83.5±107             | 0.05** |
| Education (%)             |                        |                         |                      |      |
| Illiterate                | 12                     | 13                      | 10                   | 0.27* |
| <8th grade                | 31                     | 28                      | 34                   |      |
| High school (10th grade)  | 30                     | 27                      | 32                   |      |
| Secondary school (12th grade) | 9                     | 10                      | 9                    |      |
| Graduate                  | 12                     | 13                      | 12                   |      |
| Postgraduate              | 6                      | 9                       | 3                    |      |
| Family structure (%)      |                        |                         |                      |      |
| Nuclear                   | 346 (70)               | 188 (73)                | 158 (68)             | 0.22* |
| Employment                |                        |                         |                      |      |
| Unemployed                | 223 (45)               | 45                      | 46                   | 0.18* |
| Self-employed             | 68 (14)                | 14                      | 14                   |      |
| Public sector             | 40 (8)                 | 8                       | 9                    |      |
| Private sector            | 43 (9)                 | 7                       | 10                   |      |
| Retired                   | 78 (16)                | 20                      | 12                   |      |
| Agriculture               | 23 (5)                 | 4                       | 5                    |      |
| Daily wages               | 14 (3)                 | 2                       | 4                    |      |
| Insurance (%)             |                        |                         |                      |      |
| Uninsured                 | 387 (79)               | 205 (80)                | 182 (79)             | 0.85* |

*VTDR status was at baseline (before delay in follow-up), **Student’s t-test, *Chi-squared test. VTDR: Vision-threatening diabetic retinopathy
Delayed follow-up in diabetic retinopathy

Vengadesan, et al.: Delayed follow-up in diabetic retinopathy

More than 1/2 (58%) of those who were advised routine clinical follow-up cited “my eyes were okay at the time” as the reason for the delay in follow-up compared to only 1/3 (36%) of those who were advised investigations or laser and 1/5 of those who were advised anti-VEGF injections or vitrectomy surgery (18%) (P < 0.001).

Table 2: Factors associated with delayed follow-up

| Factor                                      | Overall (n=491), n (%) | Non-VTDR (n=258), n (%) | VTDR (n=233)*, n (%) | P    |
|---------------------------------------------|------------------------|-------------------------|----------------------|------|
| Forgot date                                 | 147 (30)               | 91 (35)                 | 56 (24)              | 0.007|
| Scheduling problem                         | 29 (6)                 | 17 (7)                  | 12 (5)               | 0.50 |
| Not aware of importance of eye checkup     | 92 (18.7)              | 42 (16)                 | 50 (21)              | 0.14 |
| Eyes were okay at the time                 | 248 (50.5)             | 150 (58)                | 98 (42)              | <0.001|
| No one to accompany me                     | 201 (41)               | 102 (40)                | 99 (43)              | 0.50 |
| Financial difficulties                     | 190 (38.6)             | 82 (32)                 | 108 (47)             | 0.001|
| Leave from work unavailable                | 64 (13)                | 29 (11)                 | 35 (15)              | 0.23 |
| Too much travel time                       | 148 (30)               | 78 (30)                 | 70 (30)              | 0.96 |
| Too much waiting time in clinic            | 100 (20.3)             | 56 (22)                 | 44 (19)              | 0.44 |
| Not satisfied with previous treatment      | 26 (5.3)               | 8 (3)                   | 18 (8)               | 0.06 |
| Uncontrolled blood sugar                   | 85 (17.3)              | 42 (16)                 | 42 (18)              | 0.48 |
| Visited outside ophthalmologist            | 111 (22.6)             | 56 (22)                 | 55 (24)              | 0.61 |
| Other ailments more important than DR      | 95 (19.3)              | 55 (21)                 | 40 (17)              | 0.25 |
| Patient nonambulatory (wheelchair)         | 12 (5.5)               | 15 (5)                  | 17 (7)               | 0.37 |
| DR being treated with alternative medicine | 23 (4.7)               | 12 (5)                  | 11 (5)               | 0.97 |

*VTDR status was at baseline (before delay in follow-up), *Chi-squared test for all variables. VTDR: Vision-threatening diabetic retinopathy, DR: Diabetic retinopathy

Table 3: Diabetic retinopathy status of eyes at last and current visit and reason for follow-up

| DR at last visit | DR at current visit |
|------------------|---------------------|
|                  | No DR | Mild NPDR | Moderate NPDR | Severe NPDR | Early PDR | High-risk PDR | Lasered stable PDR | Total |
| No DR            | 11    | 2         | 8              | 1           | 2         | 1              | 0                  | 25    |
| Mild NPDR        | 0     | 31        | 10             | 2           | 1         | 2              | 0                  | 46    |
| Moderate NPDR    | 0     | 6         | 109            | 17          | 8         | 8              | 0                  | 148   |
| Severe NPDR      | 0     | 2         | 4              | 46          | 14        | 10             | 0                  | 76    |
| Early PDR        | 0     | 0         | 0              | 0           | 39        | 9              | 0                  | 48    |
| High-risk PDR    | 0     | 0         | 0              | 0           | 0         | 59             | 0                  | 59    |
| Lasered stable PDR | 0    | 0         | 0              | 0           | 0         | 89             | 89                 | 89    |
| Total            | 11    | 41        | 131            | 66          | 64        | 89             | 89                 | 491   |

NPDR: Nonproliferative diabetic retinopathy, PDR: Proliferative diabetic retinopathy, DR: Diabetic retinopathy

Table 4: Comparison of treatment advised at previous and current visit

| Treatment advised at last visit | Treatment advised at current visit |
|--------------------------------|-----------------------------------|
|                                | Regular examination | Surgery | Investigations | Laser | Anti-VEGF | Total | P    |
| Regular examination            | 244                 | 36      | 9              | 63    | 3         | 355   | <0.001|
| Surgery                        | 0                   | 12      | 0              | 9     | 0         | 21    |      |
| Investigations                 | 12                  | 2       | 3              | 7     | 1         | 25    |      |
| Laser                          | 21                  | 15      | 2              | 31    | 7         | 76    |      |
| Anti-VEGF                      | 4                   | 2       | 1              | 0     | 7         | 14    |      |
| Total                          | 281                 | 67      | 15             | 110   | 18        | 491   |      |

*Chi-squared test. VEGF: Vascular endothelial growth factor

Discussion

Patient noncompliance with scheduled follow-up presents a significant treatment barrier that has been shown to negatively affect the ultimate well-being of the patient in many ophthalmologic and nonophthalmologic diseases. In our study, a relatively large proportion of participants (47%) had

laser photoagulation, intravitreal injection, or surgery due to disease progression. More than 1/2 (58%) of those who were advised routine clinical follow-up cited “my eyes were okay at the time” as the reason for the delay in follow-up compared to only 1/3 (36%) of those who were advised investigations or laser and 1/5 of those who were advised anti-VEGF injections or vitrectomy surgery (18%) (P < 0.001).
VTDR at baseline, which was unsurprising given that this study was conducted in a tertiary referral center. Over half of the study patients reported “my eyes were okay at the time” as a reason for delaying follow-up, and the majority of these patients had non-VTDR. This response represents a significant deficit in patient understanding of DR, which often has already caused irreversible damage once symptoms develop. Knowledge of DR and its progression patterns are poor in South India, with one study reporting that only one in ten community members are aware that retinopathy is a possible sequela of diabetes.[9] Studies in Western populations have shown a similar connection between DR screening noncompliance and poor health literacy.[17–29] It is standard practice for all patients to undergo counseling by a trained staff member about their diagnosis at our facility and a relatively small proportion of our study population cited “not aware of the importance of eye checkup” as the cause for noncompliance (18.7%). This indicates that while most patients understand the importance of an eye examination, they may not be aware of the importance of eye examinations even while asymptomatic. Patient education efforts must be enhanced to emphasize the importance of early treatment of DR complications, particularly in those with non-VTDR. Extensive studies in patients with chronic disease have shown that persistent efforts toward patient education generally improve medication compliance.[30–32] and this appears to be true in ophthalmologic settings as well.[33–34] Studies regarding the impact of patient education on follow-up visit compliance are limited, but we hypothesize that greater emphasis on patient education and awareness of DR progression might affect clinic attendance similarly to medication compliance.

The second major reason for noncompliance with follow-up was “no attendant to accompany me”. Lack of escort has been observed as a major barrier to ophthalmologic care in both the developing and developed worlds.[17,29,35] DR disproportionately affects elderly patients and those with comorbid health conditions that may cause them to be even more dependent on a chaperone for assistance. In addition, a large proportion of our study population was affected by VTDR, and these patients may be more likely to require an attendant although, interestingly, patients with VTDR were not more likely to answer “yes” to this question. For those patients who have access to an attendant, the risks of delayed follow-up should be emphasized to both parties during each visit. Community-based accompaniment, which enlists volunteers to accompany patients to medical visits, has shown immense success in improving outcomes in HIV patients lacking escorts in Rwanda[36,37] but has not yet been used in the ophthalmologic setting to the best of our knowledge.

Patients cited “financial cost” as the third most common cause for follow-up noncompliance. Those with VTDR were more likely to cite this as a cause for noncompliance, and this is likely due to their lower earning potential, increased medical expenditures, and lower access to medications for glucose control. An inverse relationship between socioeconomic status and DR has been seen in some but not all studies.[17,28,38] Our institution bills patients for services in a sliding scale fashion based on the patient’s self-reported ability to pay, but transportation costs and missed days of work for the patient and/or their caretaker may represent an indirect financial burden.[22] The ultimate cost of blindness that can result from DR progression far outweighs the marginal costs of follow-up visits and procedures, and this concept should be incorporated into existing patient education programs.

Of note, 30% of patients cited “forgot date” as one of the reasons for missed follow-up. Patients with non-VTDR were significantly more likely to have forgotten their appointment date (36% vs. 26%, P = 0.02), likely because they had less severe symptoms. Text message reminders have been shown to increase attendance in ophthalmologic and nonophthalmologic settings,[40–42] and these may be employed in the future. A small but significant number of patients attributed the use of alternative medicine to their delay in follow-up. Patient education regarding the low efficacy and potential hazards of most alternative medicines available in our community must be increased to bring these numbers even lower.

There was substantial progression of DR in almost 25% of patients during the delayed follow-up period, with nearly one-third of those who initially required no treatment ultimately requiring a more aggressive treatment plan. A large number of factors can affect progression of DR including poor systemic health, and patients who are noncompliant with follow-up may also be likely to have poor general health. Nonetheless, patients with delayed follow-up may have many missed opportunities for treatment and could likely benefit from returning in a more timely fashion. Currently, it appears that those with compromised vision due to DR might find it difficult to remain economically productive leading to delayed but costlier treatments. These treatments may not always restore good vision, thus creating a vicious cycle of DR progression, vision deterioration, and draining finances. A health economics analysis to assess the economic burden levied on those who delay their follow-up compared to those who return as advised might make a beneficial future study. We also found that small percentage of patients with severe NPDR experienced regression of DR to mild and moderate NPDR. Although regression is rare, it is possible with excellent glycemic control and such patients can be used as examples to motivate other patients to maintain tight control over their blood sugar levels. A study in Chinese type 2 diabetics found a DR regression rate of 24.1%, with low baseline glucose and triglycerides due to systemic treatments being the strongest factor in disease regression.[43]

Our study has a number of limitations. Existing clinic procedures prevented physician masking to patients’ follow-up status during clinic visit, which could have inadvertently affected physician examination or treatment strategy. In addition, because data were collected in a cross-sectional manner, patients completely lost to follow-up were not included in the analysis, and reasons for nonadherence to follow-up may be distinctly different in this population. A future study might track all DR patients and use phone contact to assess reasons for noncompliance in those who do not return for follow-up. Addition of a control group with timely follow-up, matched for age, gender, and DR severity, would assist in further interpretation of the effect of delayed follow-up on DR progression. Finally, a significant proportion of patients in our study had been seen by an outside ophthalmologist during the delayed follow-up period, and these patients could have undergone sight-altering therapy that may have changed our observed changes in visual outcomes.
Conclusion

DR is a chronic disease that is largely treatable with careful follow-up and timely intervention. Although there has been a significant improvement in screening and diagnosing DR in the Indian population over the last several years, poor adherence to treatment and follow-up recommendations remains a significant barrier to ultimate improvement in the condition of these patients. Our findings represent a first step toward improving outcomes in DR patients in South India.

Acknowledgment

We acknowledge the efforts of Miss. D. Banu for diligently administering the questionnaire to all patients and Miss Devi VS for study coordination. This research was conducted without grant funding.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

1. Fenwick EK, Pesudovs K, Khadka J, Dirani M, Rees G, Wong TY, et al. The impact of diabetic retinopathy on quality of life: Qualitative findings from an item bank development project. Qual Life Res 2012;21:1771-82.
2. Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012;35:556-64.
3. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS report number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology 1981;88:583-600.
4. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 1. Early Treatment Diabetic Retinopathy Study Research Group. Arch Ophthalmol 1985;103:1796-806.
5. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: Prevalence, numerical estimates, and projections. Diabetes Care 1998;21:1414-31.
6. Ramachandran A, Snehalatha C, Dharmaraj D, Viswanathan M. Prevalence of glucose intolerance in Asian Indians. Urban-rural difference and significance of upper body adiposity. Diabetes Care 1992;15:1348-55.
7. Raman R, Rani PK, Reddi Rachepalle S, Gnanamoorthy P, Uthra S, Karampelas M, Pefkianaki M, Rees A, Gill N, Kotecha A, Hamilton R, et al. Missed hospital appointments of patients receiving ranibizumab therapy for neovascular age-related macular degeneration. Ophthalmol Ther 2015;4:43-9.
8. Barnea L, Mozer-Glassberg Y, Hojsak I, Hartman C, Shamir R. Pediatric celiac disease patients who are lost to follow-up have a poorly controlled disease. Digestion 2014;90:248-53.
9. Fletcher AE, Donoghue M, Devavaram J, Thulasiraj RD, Scott S, Abdalla M, et al. Low uptake of eye services in rural India: A challenge for programs of blindness prevention. Arch Ophthalmol 1999;117:1393-9.
10. Lee PP, Feldman ZW, Ostermann J, Brown DS, Sloan FA. Longitudinal rates of annual eye examinations of persons with diabetes and chronic eye diseases. Ophthalmology 2003;110:1952-9.
11. Griffin SJ. Lost to follow-up: The problem of defaulters from diabetes clinics. Diabet Med 1998;15 Suppl 3:514-24.
12. Ding J, Wong TY. Current epidemiology of diabetic retinopathy and diabetic macular edema. Curr Diab Rep 2012;12:346-54.
13. Raman R, Ganesan S, Pal SS, Kulothungan V, Sharma T. Prevalence and risk factors for diabetic retinopathy in Rural India. Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetic Study III (SN-DREAMS III), Report No 2. BMJ Open Diabetes Res Care 2014;2:e000005.
14. Miller AJ, Chae E, Peterson E, Ko AB. Predictors of repeated “no-showing” to clinic appointments. Am J Otolaryngol 2015;36:411-4.
15. Whiting PS, Greenberg SE, Thakore RV, Almamada VK, Ehrenfeld JM, Obremsky WT, et al. What factors influence follow-up in orthopedic trauma surgery? Arch Orthop Trauma Surg 2015;135:321-7.
16. Syed ST, Gerber BS, Sharp LK. Traveling towards disease: Transportation barriers to health care access. J Community Health 2013;38:976-93.
17. Lee BW, Sathyan P, John RK, Singh K, Robin AL. Predictors of and barriers associated with poor follow-up in patients with glaucoma in South India. Arch Ophthalmol 2008;126:1448-54.
18. Kosoko O, Quigley HA, Vitale S, Enger C, Kerrigan L, Tielsch JM. Risk factors for noncompliance with glaucoma follow-up visits in a residents’ eye clinic. Community Eye Health J 1998;11:62.
19. Lee PP, Feldman ZW, Ostermann J, Brown DS, Sloan FA. Longitudinal rates of annual eye examinations of persons with diabetes and chronic eye diseases. Ophthalmology 2003;110:1952-9.
20. Griffin SJ. Lost to follow-up: The problem of defaulters from diabetes clinics. Diabet Med 1998;15 Suppl 3:514-24.
21. Pardhan S, Mahomed I. Knowledge, self-help and socioeconomic factors in South Asian and Caucasian diabetic patients. Eye (Lond) 2004;18:509-13.
22. Fletcher AE, Donoghue M, Devavaram J, Thulasiraj RD, Scott S, Abdalla M, et al. Low uptake of eye services in rural India: A challenge for programs of blindness prevention. Arch Ophthalmol 1999;117:1393-9.
23. Barnea L, Mozer-Glassberg Y, Hojsak I, Hartman C, Shamir R. Pediatric celiac disease patients who are lost to follow-up have a poorly controlled disease. Digestion 2014;90:248-53.
24. Dodell GB, Albu JB, Attia L, McInty J, Pi-Sunyer FX, Laferrère B. The bariatric surgery patient: Lost to follow-up; from morbid obesity to severe malnutrition. Endocr Pract 2012;18:e21-5.
25. Karampelas M, Pefkianaki M, Rees A, Gill N, Kotecha A, Hamilton R, et al. Missed hospital appointments of patients receiving ranibizumab therapy for neovascular age-related macular degeneration. Ophthalmol Ther 2015;4:43-9.
26. Juzycz MS, Randhawa S, Shukairy A, Kaushal P, Gupta A, Shalauta N. Functional health literacy in patients with glaucoma in urban settings. Arch Ophthalmol 2008;126:718-24.
27. Paz SH, Varma R, Klein R, Wu J, Azen SP; Los Angeles Latino Urban Rural Epidemiology Study, I. Invest Ophthalmol Vis Sci 2015;56:4324-31.
31. Seltzer A, Roncarl I, Garfinkel P. Effect of patient education on medication compliance. Can J Psychiatry 1980;25:638-45.
32. Ali F, Laurin MY, Larivirfinkel P. Effect of patient education on medication compliance. Can J Psychiatry 1980;25:638-45.almol Vis Sci 2015;56:4324-31.3-8.itus; 126:718-24.:248‑53.98;11:62.Genetic Pharmacol 2003;10:101-6.
33. Matimba A, Woodward R, Tambo E, Ramsay M, Gwanzura L, Guramatunhu S. Tele-ophthalmology: Opportunities for improving diabetes eye care in resource-and specialist-limited Sub-Saharan African countries. J Telemed Telecare 2016;22:311-6.
34. McVeigh KA, Vakros G. The eye drop chart: A pilot study for improving administration of and compliance with topical treatments in glaucoma patients. Clin Ophthalmol 2015;9:813-9.
35. Droeg KM, Muether PS, Hermann MM, Caramoy A, Viebahn U, Kirchhof B, et al. Adherence to ranibizumab treatment for neovascular age-related macular degeneration in real life. Graefes Arch Clin Exp Ophthalmol 2013;251:1281-4.
36. Franke MF, Kaigamba F, Socci AR, Hakizamungu M, Patel A, Bagiruwige E, et al. Improved retention associated with community-based accompaniment for antiretroviral therapy delivery in rural Rwanda. Clin Infect Dis 2013;56:1319-26.
37. Thomson DR, Rich ML, Kaigamba F, Socci AR, Hakizamungu M, Bagiruwige E, et al. Community-based accompaniment and psychosocial health outcomes in HIV-infected adults in Rwanda: A prospective study. AIDS Behav 2014;18:368-80.
38. Ramachandran A, Snehala C, Vijay V, King H. Impact of poverty on the prevalence of diabetes and its complications in urban Southern India. Diabet Med 2002;19:130-5.
39. Unwin N, Whiting D, Roglic G. Social determinants of diabetes and challenges of prevention. Lancet 2010;375:2204-5.
40. Car J, Gurol-Urganci I, De Jongh T, Vodopivec-Jamsek V, Atun R. Mobile phone messaging reminders for attendance at scheduled healthcare appointments. Cochrane Database Syst Rev 2008;4:1-3.
41. Brannan SO, Dewar C, Taggerty L, Clark S. The effect of short messaging service text on non-attendance in a general ophthalmology clinic. Scott Med J 2011;56:148-50.
42. Branson CE, Clemmey P, Mukherjee P. Text message reminders to improve outpatient therapy attendance among adolescents: A pilot study. Psychol Serv 2013;10:298-303.
43. Jin P, Peng J, Zou H, Wang W, Fu J, Shen B, et al. The 5-year onset and regression of diabetic retinopathy in Chinese type 3 diabetes patients. PLoS One 2014;9:e113359.
**Factors Associated for Delayed Follow-up in Diabetic Retinopathy**

Enrollment No : ____________________________   Sign: ____________________________
I. Demographic details

Name of the patient : ____________________________   MR.No: ____________________________
DOB/Age (Yrs) : ____________________________   Sex: M / F

Marital status: □ Married   □ Unmarried   □ Widowed   □ Divorced
Place of living: □ Urban   □ Rural   City, Province:______________________________
Education: □ Illiterate   □ < 8th Std   □ High School   □ High Sec   □ Graduate   □ Post graduate
Type of family: □ Nuclear family   □ Joint family   □ No of adults in the family
Employment: □ Unemployed   □ Self-employed   □ Public sector   □ Private sector   □ Retired
         □ Agriculture   □ Daily wages
Monthly Income:______________________________
Insurance: □ Yes   □ No   If Yes:______________________________

II. Details on last visit

Date:__________________________

| Status of DR in RE  | V/A.---------- | Status of DR in LE  | V/A.---------- |
|---------------------|----------------|---------------------|----------------|
| □ No DR            | □ NVT DR      | □ No DR            | □ NVT DR      |
| NVT DR: □ NPDR     | □ Mild NPDR   | NVT DR: □ NPDR     | □ Mild NPDR   |
| □ Severe NPDR      | □ PDR         | □ Severe NPDR      | □ PDR         |
| □ HPDR             | □ DME/CSME    | □ HPDR             | □ DME/CSME    |

Previous Laser: □ Yes   □ No
         □ PRP   □ Focal

Post PRP: □ Stable   □ Unstable

Intravitreal Injection: □ Yes   □ No

Previous Surgery: □ Yes   □ No

Any other eye problem:______________________________

Any other eye problem:______________________________
Follow-up given date:---------------------------

Type of follow-up:  □ Urgent (E1)  □ Important (E2)  □ Routine (E3)

Follow-up given for:  □ Surgery  □ Investigations  □ Laser  □ Intravitreal  □ Regular Eye exam

Patient was given counseling:  □ Yes  □ No

III. Details Follow-up date

Follow-up date:

Delay in follow-up: Year:  Months:  weeks:  Days:

Reason for follow-up:  □ Vision loss  □ Follow-up  □ Other eye problem  □ Others checkup

| Status of DR in RE | V/A-------- |
|--------------------|------------|
| □ No DR  □ NVT DR  □ VT DR |

NVT DR:  □ NPDR  □ Mild NPDR  □ Mod NPDR

VT DR:  □ Severe NPDR  □ PDR  □ HPDR

□ DME/CSME

Laser Status:  □ Stable  □ Unstable

Rx Advice: □ Surg  □ Inv  □ Laser  □ I/V  □ Regular

| Status of DR in LE | V/A-------- |
|--------------------|------------|
| □ No DR  □ NVT DR  □ VT DR |

NVT DR:  □ NPDR  □ Mild NPDR  □ Mod NPDR

VT DR:  □ Severe NPDR  □ PDR  □ HPDR

□ DME/CSME

Laser Status:  □ Stable  □ Unstable

Rx Advice: □ Surg  □ Inv  □ Laser  □ I/V  □ Regular

Reason for delayed follow-up (Tick more than one if required)

I. Forgot the appointment date  □ Yes  □ No

II. Appointment scheduling problem  □ Yes  □ No

III. Not aware of importance of follow-up  □ Yes  □ No

IV. My eyes were ok at the time  □ Yes  □ No

V. No attender to accompany  □ Yes  □ No

VI. Financial cost  □ Yes  □ No

VII. Leave unavailable  □ Yes  □ No

VIII. Travel time  □ Yes  □ No

IX. Long waiting time in clinic  □ Yes  □ No

X. Not satisfied with previous treatment here  □ Yes  □ No

XI. Uncontrolled blood sugar  □ Yes  □ No

XII. Check up with other ophthalmologist  □ Yes  □ No

XIII. Other diabetic problem more important than eye---------------------------  □ Yes  □ No

XIV. Taking alternative medicine(if Yes)-----------------------------------------  □ Yes  □ No

XV. Other medical/ Physical condition:------------------------------------------  □ Yes  □ No

XVI. Incidental : □ Out of town  □ Family function  □ Death in Family  □ Foreign Travel

XVII. Others:---------------------------------------------------------------  □ Yes  □ No

Have you had your blood sugar done in the period  □ Yes  □ No

Have you consulted a diabetologist in the period  □ Yes  □ No